Are the escalating costs and intricate technical hurdles of cell therapy development causing you stress?Tune into this insightful podcast episode featuring Shin Kawamata, CEO of Cyto-Facto Inc. in Kobe, Japan, who shares his expertise and innovative solutions to these pressing issues in the cell therapy industry.Discover how to streamline your manufacturing processes, reduce costs, and enhance product quality, transforming the way you approach cell therapy development.Key Takeaways:Revolutionize Cell Manufacturing: Shin outlines how Cyto-Facto is pioneering a new business model, merging public sector support with commercial viability. Learn how this shift can accelerate the growth of the cell therapy industry.Leverage QbD in Living Systems: Discover why Quality by Design (QbD) strategies are imperative for cell therapy manufacturing.Scale Up Efficiently: Shin shares valuable insights on the challenges in scaling up cell therapies and the importance of automation, digitalization, and QbD in streamlining manufacturing processes, reducing costs, and enhancing product quality.Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.Connect with Shin:LinkedIn: www.linkedin.com/in/shin-kawamata-84647579Website: www.cytofacto.com/engGet Cell and Gene Therapy Training:Shin Kawamata's offer: The Principles and Applications of Cell Therapy Biomanufacturing, Characterization, and Regulatory: https://www.isctglobal.org/resources/training-programs/workforce-development-in-biomanufacturing401/workforce-development-in-biomanufacturingLearn more about the upcoming Cell and Gene Therapy Training program for the Asia Pacific region: contact David at hello@bruehlmann-consulting.com